EGFR and cancer: Several studies found that activation of YAP enhances the downstream gene expression of EGFR ligands such as Amphiregulin (AREG) and Neuregulin 1 (NRG-1), and ERBB3 and ERBB4, to form an autocrine loop and reinforce the MAPK signaling pathway to induce cancer progression and drug resistance [84,85,86,87,88,89].